Subject: Fwd: ILC 2018 - Industry Satellite Symposia and Mini-Workshops 11 and 12 April
From: "David Sergeenko" <[email-masked]>
To: Sopo Belkania
Date: Thu, 29 Mar 2018 14:01:46 +0400

Sent from my iPhone

Begin forwarded message:

From: EASL Office <[email-masked]>
Date: March 28, 2018 at 13:06:42 GMT+4
To: <[email-masked]>
Subject: ILC 2018 -  Industry Satellite Symposia and Mini-Workshops 11 and 12 April
Reply-To: <[email-masked]>

Dear Colleague,

Thank you for registering to the annual EASL congress. We're looking forward to welcoming you to The International Liver Congress™ 2018 in Paris.

EASL thanks its Sponsors for their support and invites you to attend the industry satellite symposia and mini-workshops listed below:

Industry symposia

Wednesday 11 April

On Wednesday 11th of April, get updated on the strategies for viral hepatitis C (HCV) treatment simplification and elimination and learn how to overcome barriers within the care continuum. Listen to experts discussing hepatic encephalopathy (HE) care optimisation and addressing diagnosis, re-admissions and the ways to drive positive changes in HE management. Get updates on the systemic therapy of unresectable HCC (uHCC), treatment planning and survival maximisation at the industry supported satellite symposia.

From Treatment Simplification to HCV Elimination: Effective Multi-Stakeholder Care, Abbvie

18:00 - 19:30 |  Main Plenary

Treatment sequencing and maximizing survival – uHCC in 2018, Bayer

18:00 - 19:00 | South 3

Driving change to optimise the HE patient journey, Norgine

18:00 - 19:30 | South 2

Thursday 12 April

Extend your knowledge on the future priorities in hepatitis B management and listen to experts discussing the prerequisites for hepatitis C care achievement. Learn about the new developments in hepatocellular carcinoma (HCC) targeted therapies and explore the pathophysiology, potential complications and unmet needs of patients with advanced non-alcoholic steatohepatitis (NASH) and HCC. Gain knowledge on NASH occurrence and treatment in sub-populations as well as the different non-invasive diagnosis methods of NASH and other liver disease screening. Finally, listen to experts discussing new perspectives in primary biliary cholangitis (PBC) management at the industry supported satellite symposia on Thursday 12th of April.

Morning

Emerging Horizons in HCC: From Palliation to Cure, Celsion

07:30 - 08:30 | West 1

Shaping tomorrow together: advances driven by commitment in HBV care, Gilead Sciences Europe Ltd

07:30 - 08:30 | South 2

Evening

Advanced NASH and HCC – The New Frontiers, Bristol-Myers Squibb

18:30 - 20:00 | South 1

Shaping tomorrow together: from aspiration to achievement in HCV care,

Gilead Sciences Europe Ltd

18:30 - 20:00 | Main Plenary

Primary Biliary Cholangitis (PBC): Old Disease, New perspectives, Intercept Pharma Europe Ltd

18:30 - 20:00 | West 1

Mini-Workshops

Thursday 12 April

Mid-infrared metabolic signature: Perspective for non-invasive diagnosis of NASH & liver diseases, Diafir

07:30 - 08:30 | West 2

NASH in sub-populations: similarities, differences and clinical development of Aramchol, Galmed

7:30 - 8:30 | West 3

You will receive the next newsletter: "ILC 2018 -  Industry Satellite Symposia and Mini-Workshops 13 and 14 April" on Friday 6 April.

To view all other industry symposia, please visit the Congress website.

We look forward to meeting with you in Paris.

The EASL Team

[email-masked]

Copyright © 2018 EASL, The Home of Hepatology, All rights reserved.

You opted to receive information from EASL.

Our mailing address is:

EASL, The Home of Hepatology

7 rue Daubin
Geneva 1203
Switzerland

Add us to your address book

Want to change how you receive these emails?

You can update your preferences or unsubscribe from this list.